in_the_evidence

In patients with confirmed rifampicin-susceptible, isoniazid-resistant tuberculosis, it is not recommended to add streptomycin or other injectable agents to the treatment regimen.

In MDR/RR-TB patients on longer regimens, a treatment duration of 15–17 months after culture
conversion is suggested for most patients; the duration may be modified according to the patient’s
response to therapy.

In MDR/RR-TB patients on longer regimens, a total treatment duration of 18–20 months is
suggested for most patients; the duration may be modified according to the patient’s response
to therapy.

Clavulanic acid should not be included in the treatment of MDR/RR-TB patients on longer
regimens.

P-aminosalicylic acid may be included in the treatment of MDR/RR-TB patients on longer
regimens only if bedaquiline, linezolid, clofazimine or delamanid are not used or if better options
to compose a regimen are not possible.

Ethionamide or prothionamide may be included in the treatment of MDR/RR-TB patients on
longer regimens only if bedaquiline, linezolid, clofazimine or delamanid are not used or if better
options to compose a regimen are not possible.

Imipenem–cilastatin or meropenem may be included in the treatment of MDR/RR-TB patients
on longer regimens.

Pyrazinamide may be included in the treatment of MDR/RR-TB patients on longer regimens.

Delamanid may be included in the treatment of MDR/RR-TB patients aged 3 years or more on
longer regimens.

Ethambutol may be included in the treatment of MDR/RR-TB patients on longer regimens.